Valtecne (VLT) Q3 2024 TU earnings summary

Executive summary

• Revenue for the first nine months of 2024 reached €24.0 million, up 0.5% year-over-year from €23.8 million.

• The medical business line grew by 17.9% year-over-year, now accounting for nearly 70% of total revenue.

• The industrial business line declined by 24.5% year-over-year, reflecting ongoing macroeconomic challenges in Europe.

• 2024 is positioned as a year of consolidation, laying the groundwork for future organic and inorganic growth.

Financial highlights

• Medical segment revenue: €16.6 million (69.2% of total), up from €14.1 million (59.0%) in 2023.

• Industrial segment revenue: €7.4 million (30.8% of total), down from €9.8 million (41.0%) in 2023.

• Total revenue for the nine-month period: €24.0 million, up 0.5% year-over-year.

Outlook and guidance

• Continued focus on the medical sector, leveraging strong demand for medical devices.

• Ongoing optimization in the industrial segment to maintain competitiveness.

• Strategic consolidation in 2024 to support future growth initiatives.